drugset / Trial / NCT07285694
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Timeline
- Start
- 2026-01-09
- Primary completion
- 2029-05
- Completion
- 2031-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AB-3028 | Cell therapy | — | Intravenous |